The volume focuses on therapeutic targets that were identified after TNF blockade and that have recently been registered or are currently under development for the treatment of rheumatoid arthritis. Each chapter discusses the biological rationale in great detail, including in vitro work and work in animal models, and where appropriate, results form clinical trials. The book is written by an international authorship of experts in this field. It is of interest to rheumatologists, immunologists, internists, the pharmaceutical industry, and to investigators in immunology and rheumatology.
Les informations fournies dans la section « Synopsis » peuvent faire référence à une autre édition de ce titre.
Vendeur : Universitätsbuchhandlung Herta Hold GmbH, Berlin, Allemagne
21 ills., 5 in color. XII, 225 p. Hardcover. Versand aus Deutschland / We dispatch from Germany via Air Mail. Einband bestoßen, daher Mängelexemplar gestempelt, sonst sehr guter Zustand. Imperfect copy due to slightly bumped cover, apart from this in very good condition. Stamped. Stamped. Progress in Inflammation Research. N° de réf. du vendeur 5664DB
Quantité disponible : 1 disponible(s)
Vendeur : Buchpark, Trebbin, Allemagne
Etat : Sehr gut. Zustand: Sehr gut | Sprache: Englisch | Produktart: Bücher | Keine Beschreibung verfügbar. N° de réf. du vendeur 3940302/12
Quantité disponible : 2 disponible(s)
Vendeur : BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Allemagne
Buch. Etat : Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -This volume focuses on therapeutic targets that were identified after TNF blockade. All these targets have recently been registered or are currently under development for the treatment of rheumatoid arthritis. Each chapter explores the biological rationale of a distinct therapeutic target in great detail. Readers will discover the latest in vitro work, animal models, and results from clinical trials. 228 pp. Englisch. N° de réf. du vendeur 9783764382377
Quantité disponible : 2 disponible(s)
Vendeur : Ria Christie Collections, Uxbridge, Royaume-Uni
Etat : New. In English. N° de réf. du vendeur ria9783764382377_new
Quantité disponible : Plus de 20 disponibles
Vendeur : GreatBookPricesUK, Woodford Green, Royaume-Uni
Etat : New. N° de réf. du vendeur 5328235-n
Quantité disponible : Plus de 20 disponibles
Vendeur : GreatBookPrices, Columbia, MD, Etats-Unis
Etat : New. N° de réf. du vendeur 5328235-n
Quantité disponible : Plus de 20 disponibles
Vendeur : Books Puddle, New York, NY, Etats-Unis
Etat : New. pp. xii + 225 2009th edition. N° de réf. du vendeur 26463665
Quantité disponible : 4 disponible(s)
Vendeur : AHA-BUCH GmbH, Einbeck, Allemagne
Buch. Etat : Neu. Druck auf Anfrage Neuware - Printed after ordering - During the past decades important breakthroughs have been made in the treatment of rheumatoid arthritis (RA). First, the implementation of low-dose methotrexate and other conventional disease-modifying anti-rheumatic drugs was introduced as an effective treatment. Second, it was recognized that early immunomodu- tory treatment is crucial for controlling the disease and its long-term destructive effects more effectively. Parallel advances in research on the pathogenesis of RA and cytokine biology converged in identifying tumor necrosis factor (TNF) as a key factor in inflammation and matrix destruction. The concept arose that elevated TNF concentrations at the sites of inflammation were driving disease pathology, and the removal of excess TNF from sites of inflammation became a therapeutic goal. Clearly, TNF blockade has revolutionized the treatment of RA, as well as other immune-mediated inflammatory diseases. Anti-TNF treatment results in cli- cal benefit in a significant proportion of the patients, and it has provided proof of concept for the principle of targeted therapy. Despite the impressive disease-modifying effects of the TNF blockers, not all patients respond, and patients who exhibited an initial response may lose response due to the development of anti-drug antibodies (human anti-chimeric antibodies and human anti-human antibodies, respectively) and perhaps as a result of escape mechanisms related to the disease process. In fact, the majority of the patients still have disease activity in at least one or two actively inflamed joints. N° de réf. du vendeur 9783764382377
Quantité disponible : 2 disponible(s)
Vendeur : Majestic Books, Hounslow, Royaume-Uni
Etat : New. Print on Demand pp. xii + 225 Illus. N° de réf. du vendeur 7384302
Quantité disponible : 4 disponible(s)
Vendeur : Biblios, Frankfurt am main, HESSE, Allemagne
Etat : New. pp. xii + 225. N° de réf. du vendeur 18463675
Quantité disponible : 1 disponible(s)